Oncology

Your Article Summary

See Latest Articles

Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer
European Journal of Cancer, 10/20/09

Dauplata J et al. – Findings of this study support a possible relationship between OED and the use of ovulation-stimulating drugs. The increased dysplasia score in stimulated and genetic risk ovaries might be consistent with progression towards neoplastic transformation, and may justify the use of the term dysplasia or intraepithelial ovarian neoplasia. The observation of dysplasia in the stimulated group may differentiate women at risk. Conversely, the fact that the dysplasia profile after stimulation differs from that in genetic risk ovaries suggests that ovarian stimulation may predispose to a different evolution.

• 124 patients who had undergone salpingo-oophorectomies or ovarian cystectomies between 1990 and 2005 reviewed
• Divided into 3 groups: (1) previous in vitro fertilisation (n=35); (2) prophylactic oophorectomies for genetic risk (n=27) and (3) fertile non-cancerous controls (n=62)
• 11 cytological and architectural epithelial features defined and dysplasia score calculated to quantify ovarian epithelial abnormalities

• Mean dysplasia score significantly higher in genetic risk and stimulated ovary groups than controls
• Cytological and architectural abnormalities more frequent in genetic risk group, while profile of abnormalities different in genetic risk and stimulated groups

Today in Gynecologic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Ovarian cancer screening and early detection
Women's Health, 11/04/09

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
New England Journal of Medicine, 11/06/09

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09

See All of Gynecologic Oncology